

Avance reports 34% rise in clinical trials in Aus, NZ

May 12, 2020 | News

Avance Clinical, which has been offering CRO services for more than two decades for early phase trials, reports 95 new trials were registered in the past 30 days as recorded in Australian and New Zealand registry ANZCTR.org.au



The Australian CRO, Avance Clinical, said there was a 34% increase in the number of international trials registered in Australia and New Zealand in the past month compared with the previous month, as both countries are among the first globally to emerge from the COVID-19 crisis. (ClinicalTrials.gov)

Register for the Biospectrum Asia and Avance Clinical Webinar here. <https://biospectrumasia.com/avance-webinar>

Community and business rules are changing as Australia and New Zealand demonstrate real success in managing the COVID-19 pandemic.

Data from the Australian and New Zealand registry [ANZCTR.org.au](https://anzctr.org.au) shows there were 95 new trials registered in the past 30 days.

Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with more than 20-years of experience in managing early phase trials.

Avance Clinical is based in Adelaide, South Australia with a strong operational presence and a network of proven sites across Australia and New Zealand.

In addition to the impressive COVID-19 management, a key factor in sponsor demand is the speed, and attractive cost of running trials in Australia including:

- The Australian Government financial rebate of more than 40% on clinical trial spend
- No IND required for clinical trials and streamlined regulatory processes
- Advanced medical, research and scientific community, leading investigators and KOLs, and modern medical facilities

Watch video - how we work during the COVID-19 pandemic here. <https://www.avancecro.com/news/news-about-avance-clinical-covid-19-capabilities/>

Avance Clinical CEO Yvonne Lungershausen, who has a background in pure research, said sites were using tools like eSourcing and eConsent to ensure studies stay on track.

“Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical

trials.”

For more information about the benefits of running your next study in Australia contact us:
<https://www.avancecro.com/contact-us/>